Loading...

APC anti-human CD279 (PD-1) Antibody

Pricing & Availability
Clone
EH12.2H7 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, PDCD1
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
a-EH12dot2H7_APC_022508
PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) APC (filled histogram) or mouse IgG1, κ APC (open histogram).
  • a-EH12dot2H7_APC_022508
    PHA-stimulated (day-3) human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) APC (filled histogram) or mouse IgG1, κ APC (open histogram).
  • b-EH12-2H7_APC_CD279_2_Antibody_103024
    Human peripheral blood lymphocytes were stained with CD279 (clone EH12.2H7) APC and CD3 (clone UCHT1) PerCP/Cyanine5.5.
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
329907 25 tests 120€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
329908 100 tests 252€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Programmed cell death 1 (PD-1), also known as CD279, is a 55 kD member of the immunoglobulin superfamily. CD279 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) in the cytoplasmic region and plays a key role in peripheral tolerance and autoimmune disease. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. PD-L1 (B7-H1) and PD-L2 (B7-DC) are ligands of CD279 (PD-1) and are members of the B7 gene family. Evidence suggests overlapping functions for these two PD-1 ligands and their constitutive expression on some normal tissues and upregulation on activated antigen-presenting cells. Interaction of CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of ligand binding1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections13, and spatial biology (IBEX)15,16. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
  3. Velu V, et al. 2007. J. Virol. 81:5819. (FA)
  4. Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
  5. Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
  6. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
  7. Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
  8. Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
  9. Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
  10. Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
  11. Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
  12. Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
  13. Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
  14. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
  15. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  16. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Xu C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:327. PubMed
  2. Gao Y, et al. 2023. JCI Insight. 8: . PubMed
  3. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  4. Cao B, et al. 2022. Nat Commun. 13:6203. PubMed
  5. Cheng K, et al. 2023. Int J Mol Sci. 24:. PubMed
  6. Segaliny AI, et al. 2023. Commun Biol. 6:380. PubMed
  7. Shi J, et al. 2023. Front Immunol. 14:1166052. PubMed
  8. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  9. Imai H, et al. 2023. iScience. 26:106822. PubMed
  10. Montes de Oca M, et al. 2016. Cell Rep. 17:399-412. PubMed
  11. Cheng L, et al. 2021. Cancer Immunol Immunother. Online ahead of print. PubMed
  12. Zhang Y, et al. 2020. Oncol Lett. 1.053472222. PubMed
  13. Wang Z, et al. 2018. Nat Commun. 9:824. PubMed
  14. Panwar B, et al. 2021. Genome Res. 31:659. PubMed
  15. Porsche CE, et al. 2021. JCI Insight. 6:. PubMed
  16. Jia X, et al. 2021. Clin Transl Immunology. 10:e1336. PubMed
  17. Daugan MV, et al. 2021. Cancer Immunol Res. 9:891. PubMed
  18. Yamaguchi A, et al. 2021. J Thorac Dis. 13:5430. PubMed
  19. Wang S, et al. 2021. Exp Ther Med. 21:37. PubMed
  20. Liao JB, et al. 2021. J Immunother Cancer. 9:. PubMed
  21. Kraig E, et al. 2018. Exp Gerontol. 105:53. PubMed
  22. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  23. Miles B, et al. 2015. Nat Commun. 6: 8608. PubMed
  24. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  25. Todorova D, et al. 2020. EBioMedicine. 62:103120. PubMed
  26. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  27. Rodda LB, et al. 2020. Cell. 184(1):169-183.e17. PubMed
  28. Zhang J, et al. 2022. Nature. 609:369. PubMed
  29. Cai J, et al. 2021. eLife. 10:00. PubMed
  30. Martín–Gayo E, et al. 2020. Cell Rep. 30:984. PubMed
  31. Zhu Y, et al. 2019. Cell Stem Cell. 25:542. PubMed
  32. Rasmussen TA, et al. 2022. Cell Rep Med. 3:100766. PubMed
  33. Xu H, et al. 2013. J Leukoc Biol. 93:943. PubMed
  34. Miles B, et al. 2016. PLoS Pathog. 12:e1005924. PubMed
  35. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
  36. Paul S, et al. 2021. Sci Transl Med. 13:. PubMed
  37. Wang D, et al. 2017. Leukemia. 10.1038/leu.2017.69. PubMed
  38. Zhao Y et al. 2018. Cell reports. 24(2):379-390 . PubMed
  39. Ng KW, et al. 2019. eLife. 0.333333333333333. PubMed
  40. Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed
  41. Liu Y, et al. 2018. Cancer Cell. 33:480. PubMed
  42. Niu C, et al. 2018. Front Immunol. 9:1759. PubMed
  43. Mathewson ND, et al. 2021. Cell. 184(5):1281-1298.e26. PubMed
  44. Frasca D, et al. 2021. Front Immunol. 616650:12. PubMed
  45. Frasca D, et al. 2018. PLoS One. 13:e0197472. PubMed
  46. Renner K, et al. 2020. Cell Reports. 29(1):135-150.e9.. PubMed
  47. Beyer M, et al. 2016. Nat Immunol. 17:593-603. PubMed
  48. Blackburn M, et al. 2015. J Immunol. 195: 3227 - 3236. PubMed
  49. Tian X, et al. 2015. J Immunol. 194:3873. PubMed
  50. Schultheiß C, et al. 2020. Immunity. 53(2):442-455.e4.. PubMed
  51. Zou F, et al. 2019. Nat Commun. 10:4109. PubMed
  52. Lecciso M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01918. PubMed
  53. Tan EE, et al. 2020. J Clin Invest. 130:5817. PubMed
  54. Chew G, et al. 2016. PLoS Pathog. 12: 1005349. PubMed
  55. Javed A, et al. 2015. PLoS One. 10: 0142086. PubMed
RRID
AB_940473 (BioLegend Cat. No. 329907)
AB_940473 (BioLegend Cat. No. 329908)

Antigen Details

Structure
Immunoglobulin superfamily
Distribution

Transiently expressed on CD4- CD8- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells

Ligand/Receptor
B7-H1 (also known as PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, Lymphocytes, T cells, Thymocytes, Tregs
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Gene ID
5133 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD279 Reagents Request Custom Conjugation
Description Clone Applications
Brilliant Violet 421™ anti-human CD279 (PD-1) EH12.2H7 FC
Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC-F
FITC anti-human CD279 (PD-1) EH12.2H7 FC
PE anti-human CD279 (PD-1) EH12.2H7 FC,SB
APC anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 647 anti-human CD279 (PD-1) EH12.2H7 FC
PerCP/Cyanine5.5 anti-human CD279 (PD-1) EH12.2H7 FC
APC/Cyanine7 anti-human CD279 (PD-1) EH12.2H7 FC
Pacific Blue™ anti-human CD279 (PD-1) EH12.2H7 FC
PE/Cyanine7 anti-human CD279 (PD-1) EH12.2H7 FC
Purified anti-human CD279 (PD-1) (Maxpar® Ready) EH12.2H7 FC,CyTOF®
Brilliant Violet 605™ anti-human CD279 (PD-1) EH12.2H7 FC
Ultra-LEAF™ Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC-F
Brilliant Violet 711™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 785™ anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 510™ anti-human CD279 (PD-1) EH12.2H7 FC
Biotin anti-human CD279 (PD-1) EH12.2H7 FC
PE/Dazzle™ 594 anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 488 anti-human CD279 (PD-1) EH12.2H7 FC
PerCP anti-human CD279 (PD-1) EH12.2H7 FC
GoInVivo™ Purified anti-human CD279 (PD-1) EH12.2H7 FC,Block,IHC
Brilliant Violet 650™ anti-human CD279 (PD-1) EH12.2H7 FC
Alexa Fluor® 700 anti-human CD279 (PD-1) EH12.2H7 FC
APC/Fire™ 750 anti-human CD279 (PD-1) EH12.2H7 FC
TotalSeq™-A0088 anti-human CD279 (PD-1) EH12.2H7 PG
TotalSeq™-B0088 anti-human CD279 (PD-1) EH12.2H7 PG
TotalSeq™-C0088 anti-human CD279 (PD-1) EH12.2H7 PG
Brilliant Violet 750™ anti-human CD279 (PD-1) EH12.2H7 FC
TotalSeq™-D0088 anti-human CD279 (PD-1) EH12.2H7 PG
PE/Fire™ 640 anti-human CD279 (PD-1) EH12.2H7 FC
PE/Cyanine5 anti-human CD279 (PD-1) EH12.2H7 FC
PE/Fire™ 744 anti-human CD279 (PD-1) EH12.2H7 FC
Spark Red™ 718 anti-human CD279 (PD-1) EH12.2H7 FC
Brilliant Violet 570™ anti-human CD279 (PD-1) EH12.2H7 FC
Go To Top Version: 2    Revision Date: 01.22.2015

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account